Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GMPS | P49915 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.54 |
| ▸ | SLC28A1 | O00337 | 2/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.48 |
| ▸ | PI4KA | P42356 | 2/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.48 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | AHCY | P23526 | 6/20 | 0.46 |
| ▸ | ADA | P00813 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4519528 | 0.93 | GMPS (0.60) | GMPSADORA3ADORA2ASLC28A1PI4K2A | |
| SCHEMBL4519522 | 0.93 | GMPS (0.60) | GMPSADORA3ADORA2ASLC28A1PI4K2A | |
| SCHEMBL20839261 | 0.88 | GMPS (0.60) | GMPSADORA3ADORA2ASLC28A1PI4K2A | |
| SCHEMBL22367660 | 0.88 | GMPS (0.60) | GMPSADORA3ADORA2ASLC28A1PI4K2A | |
| SCHEMBL15524961 | 0.82 | AHCY (0.49) | GMPSADORA3ADORA2ASLC28A1AHCY | |
| SCHEMBL10751549 | 0.80 | AHCY (0.45) | GMPSADORA3ADORA2ASLC28A1AHCY | |
| Decoyinine SCHEMBL22430502 | 0.77 | GMPS (1.00) | GMPSADORA3ADORA2ASLC28A1PI4K2A | |
| SCHEMBL21591026 | 0.77 | ADORA2A (0.53) | GMPSADORA3ADORA2ASLC28A1PI4K2A | |
| Psicofuranine SCHEMBL9389898 | 0.77 | GMPS (0.61) | GMPSADORA3ADORA2ASLC28A1PI4K2A | |
| Psicofuranine SCHEMBL691065 | 0.77 | GMPS (0.61) | GMPSADORA3ADORA2ASLC28A1PI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-H09510696-A | — | — | 1997-10-28 | — | — | JP | claimed |
| EP-0737077-A1 | HEPATOCYTE-TARGETED DRUG CONJUGATES | TARGETECH, INC. (US) | 1996-10-16 | — | — | EP | claimed |
| WO-1995018636-A2 | HEPATOCYTE-TARGETED DRUG CONJUGATES | TARGETECH INC (US) | 1995-07-13 | — | — | WO | claimed |
| US-20240100021-A1 | Combination Therapy Schedules to Treat Cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-03-28 | — | — | US | disclosed |
| EP-2563367-A1 | METHODS OF TREATING RETROVIRAL INFECTIONS AND RELATED DOSAGE REGIMES | Chimerix, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| EP-2534150-A2 | METHODS OF TREATING VIRAL INFECTION | Chimerix, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011139709-A2 | METHODS OF TREATING RETROVIRAL INFECTIONS AND RELATED DOSAGE REGIMES | CHIMERIX, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011100698-A2 | METHODS OF TREATING VIRAL INFECTION | CHIMERIX, INC. (US) | 2011-08-18 | — | — | WO | disclosed |
| EP-0737077-A1 | HEPATOCYTE-TARGETED DRUG CONJUGATES | TARGETECH, INC. (US) | 1996-10-16 | — | — | EP | disclosed |
| WO-1995018636-A2 | HEPATOCYTE-TARGETED DRUG CONJUGATES | TARGETECH INC (US) | 1995-07-13 | — | — | WO | disclosed |
| EP-0212956-A1 | Guanine derivatives | GLAXO GROUP LIMITED (GB) | 1987-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100021-A1 | Combination Therapy Schedules to Treat Cancer | TYMP, DPYD, TP53 | GMPS 1049/4885ADORA3 729/4885ADORA2A 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.